|Mr. Allan Oberman||CEO & Director||141.67k||N/A||59|
|Mr. Francesco Tallarico||Chief Legal Officer & Sec.||423.01k||N/A||N/A|
|Mr. Adrian A. de Saldanha||Exec.||1.56M||N/A||56|
|Mr. Adeel Ahmad||Chief Financial Officer of Concordia International Segment||909.58k||N/A||N/A|
|Mr. David J. Price||Chief Financial Officer||N/A||N/A||54|
Concordia International Corp., a specialty pharmaceutical company, through its subsidiaries, owns or licenses a portfolio of branded and generic prescription products. It operates through three segments: Concordia International, Concordia North America, and Orphan Drugs. The Concordia International segment owns or licenses a portfolio of branded and generic prescription products to wholesalers, hospitals, and pharmacies. This segment's products include Tetroxin drug for severe hypothyroid states; Macrobid/Macrodantin to treat bladder infections, such as cystitis and urinary tract infections; Fucithalmic, a topical gel treatment for patients suffering with a bacterial infection of the surface lining of the front of the eye; and Eltroxin, levothyroxine sodium that treats patients with an underactive thyroid gland. The Concordia North America segment provides Donnatalm, which is used as adjunctive therapy for irritable bowel syndrome; Plaquenil and Plaquenil AG to treat rheumatoid arthritis and manage the complications of lupus, as well as suppress acute attacks from certain strains of malaria; and Zonegran, an anti-seizure drug indicated for adjunctive therapy in the treatment of partial seizures in adults with epilepsy. The Orphan Drugs segment develops Photofrin, a light-based cancer treatment that combines a photosensitizing drug called porfimer sodium with a specific type of light to attack cancer cells. The company sells through direct sales and local partnerships. The company was formerly known as Concordia Healthcare Corp. and changed its name to Concordia International Corp. in 2016. Concordia International Corp. is headquartered in Oakville, Canada.
Concordia International Corp.’s ISS Governance QualityScore as of February 1, 2018 is 5. The pillar scores are Audit: 1; Board: 5; Shareholder Rights: 3; Compensation: 7.